Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SNDX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSyndax Pharmaceuticals reports Q4 and full-year fiscal 2026 financial results
Filed April 30, 2026 · Period ending April 30, 2026 · ~1 min read
Key Changes
-
high
Company announced financial results for the quarter and year ended March 31, 2026 via press release and investor presentation. Specific financial metrics are contained in the attached exhibits.
Item 7.01 view on EDGAR → -
low
Filing is procedural in nature, with detailed financial performance data provided in separate press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2) rather than in the 8-K body.
8-K: Exhibits verify on EDGAR →
Summary
Syndax Pharmaceuticals filed an 8-K to announce its fourth quarter and full fiscal year 2026 financial results for the period ended March 31, 2026. This is a routine quarterly earnings disclosure, with the company releasing results through a press release and investor presentation rather than detailing them in the filing itself. Retail investors should review the attached exhibits (99.1 and 99.2) for the actual financial metrics, including revenue, cash position, operating expenses, and any pipeline updates.
The 8-K filing itself is procedural and contains no substantive financial data. Watch for analyst reactions and management commentary on the earnings call, which typically accompanies such releases. Key items to monitor include commercial performance of any marketed products, clinical trial progress, cash runway, and updated guidance for fiscal 2027.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 30, 2026, Syndax Pharmaceuticals, Inc. (the “Company”) issued a press release and presentation announcing its financial results for the quarter and year ended March 31, 2026.
The company disclosed its financial results for the fourth quarter and full fiscal year ended March 31, 2026 through a press release and presentation. The actual financial details are contained in the attached exhibits rather than in the body of this 8-K filing.
Event · Item 9.01 — Financial Statements and Exhibits
Syndax filed an 8-K attaching a press release and corporate presentation dated April 30, 2026, with no material event details disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1 | Press Release, dated April 30, 2026 | 99.2 Corporate Presentation, dated April 30, 2026
The 8-K lists two exhibits: a press release and a corporate presentation, both dated April 30, 2026. The filing body provides no details about the content or purpose of these documents, making this a procedural disclosure.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify